An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.
Gastric Cancer
Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST), 12 months|Progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST), 12 months|Overall survival according to Response Evaluation Criteria in Solid Tumors (RECIST), 12 months
Documentation of the testing process for HER2-positive tumors, 12 months|Assessment of implementation of guidelines and recommendations of Herceptin administration in routine clinical practice, 12 months|Documentation of backbone chemotherapy treatment and concomitant medication, 12 months|Quality of Life questionnaire, 12 months|Surveillance of pain intensity and analgesic consumption, 12 months|Surveillance of weight change, 12 months|Safety (incidence of adverse events), 12 months
This observational, multicenter study will assess the efficacy and safety of Herceptin (trastuzumab) in routine clinical practice in patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-esophageal junction. Data from patients will be collected for approximately 12 months.